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Abstract
 
Trypanosoma cruzi
 
 is the etiological agent of Chagas’ disease. So far, first choice anti-chagasic
drugs in use have been shown to have undesirable side effects in addition to the emergence of
parasite resistance and the lack of prospect for vaccine against 
 
T. cruzi
 
 infection. Thus, the iso-
lation and characterization of molecules essential in parasite metabolism of the anti-chagasic
drugs are fundamental for the development of new strategies for rational drug design and/or
the improvement of the current chemotherapy. While searching for a prostaglandin (PG) F
 
2
 
 
 
synthase homologue, we have identified a novel “old yellow enzyme” from 
 
T. cruzi
 
 (TcOYE),
cloned its cDNA, and overexpressed the recombinant enzyme. Here, we show that TcOYE
reduced 9,11-endoperoxide PGH
 
2 
 
to PGF
 
2
 
  
 
as well as a variety of trypanocidal drugs. By elec-
tron spin resonance experiments, we found that TcOYE specifically catalyzed one-electron re-
duction of menadione and 
 
 
 
-lapachone to semiquinone-free radicals with concomitant gener-
ation of superoxide radical anions, while catalyzing solely the two-electron reduction of
nifurtimox and 4-nitroquinoline-
 
N
 
-oxide drugs without free radical production. Interestingly,
immunoprecipitation experiments revealed that anti-TcOYE polyclonal antibody abolished
major reductase activities of the lysates toward these drugs, identifying TcOYE as a key drug-
metabolizing enzyme by which quinone drugs have their mechanism of action.
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Introduction
 
Old yellow enzyme (OYE)
 
* 
 
was discovered in the 1930s
and first used to demonstrate the requirement of a cofactor
for catalysis by enzymes (1, 2). This enzyme has since been
identified in yeasts (1, 3), plants (4), and bacteria (5, 6) but
not in animals. Despite extensive biochemical and spectro-
scopic characterization, the physiological function of OYE
has remained obscure and the possible involvement of it in
the pathological processes of human disease is unknown.
Chagas’ disease affects more than 20 million people in
South America (7) where the disease is a major public
health and economic problem. The limited success and lia-
bility of the current treatments for Chagas’ disease has led
to the search for new anti-trypanosomal drugs. Naph-
thoquinones such as menadione (2-methyl-1,4-naphtho-
quinone) and 
 
 
 
-lapachone (3,4-dihydro-2,2-dimethyl-
2
 
H
 
-naphtho[1,2-b]pyran-5,6-dione), and nitroheterocycles,
i.e., 4-nitroquinoline-
 
N
 
-oxide, nifurtimox (3-methyl-
 
N
 
-
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Abbreviations used in this paper: 
 
AA, arachidonic acid; ESR, electron
 
spin resonance; GSH, glutathione; IPTG, isopropyl-
 
 
 
-
 
d
 
-thiogalactopyra-
noside; LC-MS, liquid chromatography-mass spectrometry; ORF, open
reading frame; OYE, old yellow enzyme; TcOYE, 
 
Trypanosoma cruzi
 
OYE; TR, trypanothione reductase. 
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Trypanosoma cruzi
 
 naphthoquinone- and nitroheterocycle-metabolizing enzyme
 
[(5-nitro-2-furanyl)-methylene]-4-thiomorpholinamine
1,1-dioxide), and benznidazole (2-nitro-
 
N
 
-[phenylmethyl]-
1H-imidazole-1-acetamide) have been used for several de-
cades as trypanocidal drugs (nifurtimox and benznidazole
provided by S.R. Wilkinson, London School of Hygiene
and Tropical Medicine, London, United Kingdom; refer-
ences 8–11). These compounds are thought to exert their
trypanocidal action by the generation of free radicals
through a redox cycling process in which the drugs are en-
zymatically reduced to form drug anion radicals. Under
aerobic conditions these radicals reduce oxygen nonenzy-
matically, leading to drug regeneration and formation of
superoxide radical anions that cause oxidative stress and cell
death in susceptible parasites. Several studies have reported
free radical production upon the addition of these drugs to
either intact cells or lysates of 
 
Trypanosoma cruzi
 
 (12–15).
Although naphthoquinones and nitroheterocyclic drugs
have been shown to undergo the redox cycling process
within the parasite, the precise mechanism by which the
drugs act and the involvement of parasite molecules in the
redox cycling process have not yet been fully elucidated.
We have been investigating the metabolism of arachi-
donic acid (AA) in parasitic protozoa and have previously
shown PG production in 
 
Plasmodium falciparum
 
 (16) and
 
Trypanosoma brucei
 
 (17). To gain additional insight into PG
synthesis and function in trypanosomatids, we extended
our investigation to 
 
T. cruzi
 
 and identified a 
 
T. cruzi
 
 OYE
(TcOYE) whose gene shares limited sequence identity (16–
28%) with OYEs described earlier. In this study, we show
that TcOYE catalyzes PGF
 
2
 
  
 
synthesis in addition to the
reduction of a variety of trypanocidal drugs. Moreover,
anti-TcOYE polyclonal antibody abolishes the reductase
activity of 
 
T. cruzi
 
 epimastigote lysates toward naphtho-
quinone and nitroheterocyclic drugs, implicating TcOYE
for the first time as a subversive target by which quinone
drugs have their mechanism of action.
 
Materials and Methods
 
Sequence Data.
 
The nucleotide sequence data reported in this
paper is available from GenBank/EMBL/DDBJ under accession
no. AB075599.
 
Parasites and Cultivation.
 
Epimastigotes (the insect form) of 
 
T.
cruzi
 
 clone Y
 
NIH 
 
(18) were grown at 26
 
 
 
C in liver infusion tryp-
tose liquid medium, supplemented with 20 
 
 
 
g/ml hemin, 10%
heat-inactivated fetal calf serum, 100 U/ml penicillin, and 100
 
 
 
g/ml streptomycin as previously described (19).
 
Enzyme Assays, PG Extraction, Analysis, and Quantification.
 
For PG production from AA, 
 
T. cruzi
 
 epimastigotes (2–4 
 
  
 
10
 
9
 
cells) were ruptured as previously described (17) and the lysates
were used in a reaction mixture containing 100 mM sodium
phosphate, pH 7.0, 2 
 
 
 
M hematin, 5 mM tryptophan, 1 mM
AA, and 200 
 
 
 
l lysates in a final volume of 500 
 
 
 
l. The mixture
was incubated at 37
 
 
 
C for 30 min, and then the reaction was
stopped by the addition of 100 
 
 
 
l of 1 M HCl and 6 vol cold
ethyl acetate. After the addition of [
 
3
 
H]PGD
 
2
 
, [
 
3
 
H]PGE
 
2
 
, and
[
 
3
 
H]PGF
 
2
 
  
 
(60 Bq each per assay; NEN Life Science Products)
used as tracers to determine the recovery during extractions, PGs
recovered from the incubation of parasite lysates were extracted
 
and separated by HPLC as previously described (16, 17, 20). The
resulting PGD
 
2
 
, PGE
 
2
 
, and PGF
 
2
 
  
 
were quantified by enzyme
immunoassay with their respective EIA kits (Cayman Chemical).
Aerobic and/or anaerobic synthesis of PGF
 
2
 
  
 
from PGH
 
2 
 
was
performed using a standard reaction mixture that contained 100
mM sodium phosphate, pH 7.0, a diluted amount of enzyme, and
the cofactor, i.e., NADPH-generating system (100 
 
 
 
M NADP
 
 
 
,
100 
 
 
 
M glucose-6-phosphate, and 1 unit glucose-6-phosphate
dehydrogenase) or 100 
 
 
 
M NADPH or NADH, in a final vol-
ume of 100 
 
 
 
l. For anaerobic reactions, mixtures were bubbled
with argon gas for 5 min. The reaction was started by the addi-
tion of 1 
 
 
 
l of 500 
 
 
 
M 1-[
 
14
 
C]PGH
 
2 
 
(2.04 Gbq/mmol) per-
formed at 37
 
 
 
C for 2 min and was terminated by the addition of
250 
 
 
 
l of a stop solution (diethyl ether/methanol/2 M citric acid
[30:4:1 vol/vol/vol]). To test the nonenzymatic formation of
PGF
 
2
 
 
 
, we incubated the reaction mixture containing all the
components in the absence of the enzyme. The organic phase (50
 
 
 
l) was applied to 20 
 
  
 
20-cm silica gel plates (Merck) at 4
 
 
 
C
and the plates were developed with a solvent system of diethyl
ether/methanol/acetic acid (90:2:1 vol/vol/vol) at 
 
 
 
20
 
 
 
C. The
radioactivity on the plates was monitored and analyzed by Fluo-
rescent Imaging Analyzer FLA 2000 and Mac Bas V2.5 software
(Fuji Photo Film).
For nifurtimox inhibition of TcOYE reductase activity, vari-
ous concentrations of the drug were preincubated with an appro-
priate amount of enzyme and the reaction was started by the ad-
dition of NADPH and PGH
 
2
 
. Spectrophotometric assays were
performed in a standard reaction mixture (1 ml) containing 100
mM sodium phosphate, pH 7.0, an appropriate amount of en-
zyme, and 100 
 
 
 
M NADPH or NADH. We incubated the mix-
ture at 37
 
 
 
C for 2 min under anaerobic conditions before adding
substrates to initiate the reaction. NADPH and/or NADH oxi-
dation was monitored by the decrease in absorbance at 340 nm.
Blanks without enzyme or substrate were included. To investi-
gate the conversion of PG carbonyl or hydroxyl groups into al-
cohol or keto-oxo groups, 1-[
 
14
 
C]PGD
 
2
 
, PGE
 
2
 
, and PGF
 
2
 
  
 
(40
 
 
 
M each) produced as previously described (17) were incubated
with TcOYE and the resulting products were analyzed by thin
layer chromatography.
 
Liquid Chromatography-Mass Spectrometry (LC-MS) Analysis.
 
LC-MS analyses were run on a Waters Alliance LC-MS system
equipped with 2690 separation module, 996 photodiode array,
ZQ4000 mass detectors, and fused with an Inertsil-ODS3 col-
umn (GL Sciences Inc.) that had a 2.1 mm ID, 250-mm length,
and 37
 
 
 
C column temperature. We produced PGF
 
2
 
  
 
by incubat-
ing 80 
 
 
 
g cold 9,11-endoperoxide PGH
 
2 
 
(Cayman Chemical)
with 100 
 
 
 
g TcOYE as described above. After stopping the reac-
tion, PGF
 
2
 
  
 
was extracted, dried, redissolved in 100 
 
 
 
l ethanol,
and then analyzed by LC-MS.
 
Protein Fractionation. T.  cruzi
 
 epimastigotes (10
 
10 
 
cells) were
ruptured by hypotonic lysis. Soluble proteins resulting from dif-
ferential centrifugation at 3,000 
 
g
 
 for 15 min and then at 100,000 
 
g
 
for 1 h at 4
 
 
 
C were fractionated with ammonium sulfate. The ac-
tive fraction (20–80% saturation) resuspended in PBS was loaded
onto a Hiload 16/60 Superdex 200 pg (Amersham Biosciences)
gel filtration column and eluted with the same buffer. Active frac-
tions were pooled, concentrated by the use of Centricon centrif-
ugal filters with a molecular weight cut-off of 3,000 (Millipore),
dialyzed against 20 mM sodium phosphate, pH 7.0, additionally
loaded onto a Resource PHE Hydrophobic interaction column
(Amersham Biosciences) that had been equilibrated with 2 M
ammonium sulfate in 20 mM sodium phosphate, pH 7.0, and
eluted with a decreasing linear gradient of 2–0 M ammonium sul- 
1243
 
Kubata et al.
fate in the same buffer containing 1% (vol/vol) Tween 20. The
active peak was dialyzed against 20 mM Tris/Cl, pH 8.0, and ap-
plied to a HiPrep 16/10 DEAE ion exchange column (Amersham
Biosciences) that had been equilibrated with the same buffer. The
elution was performed with an increasing linear gradient of 0–400
mM NaCl in the same buffer. The active fraction was additionally
purified by gel filtration on a Hiload 16/60 Superdex 200 pg
column.
Protein concentration was determined by the use of bicincho-
ninic acid reagent (Pierce Chemical Co.) with BSA as a standard
according to the manufacturer’s protocol. The purity of the pro-
tein was assessed by SDS-PAGE on 14% (wt/vol) gels, and the
gels were stained with sypro orange (Bio-Rad Laboratories) or
Coomassie Brilliant Blue (Daiichi Pure Chemicals).
Absorbance spectra of oxidized and reduced TcOYE were
measured on a DU
 
® 
 
640 spectrophotometer (Beckman Coulter)
by using 80 
 
 
 
l TcOYE (4 
 
 
 
g/
 
 
 
l) and 100 
 
 
 
M NADPH (re-
duced TcOYE) in 0.1 M sodium phosphate buffer, pH 7.0. The
spectra of the oxidized or reduced flavin were read at 37
 
 C be-
tween 300–600 nm.
In-Gel Protein Digestion and Partial Amino Acid Sequence Analy-
sis. 20  g pure TcOYE was separated by SDS-PAGE on a
12.5% acrylamide gel and stained with Coomassie Brilliant Blue.
The stained protein band was in-gel digested with lysyl-endo-
peptidase in Tris/Cl buffer, pH 8.5, at 35 C for 20 h according
to Rosenfeld et al. (21). Peptides were purified on a C18 reverse
phase HPLC column as described by Rosenfeld et al. (21) and
the amino acid sequence analysis was performed on a Shimadzu
PSQ-1 system protein sequencer (Shimadzu Scientific Instru-
ments).
PCR Amplification, cDNA Cloning, and Sequencing. Total RNA
was extracted from T. cruzi epimastigote cells (2–4   109 cells)
with ISOGEN (a guanidine HCl/phenol procedure; Nippon
Gene). First strand cDNA was synthesized by RT-PCR using
avian myeloblastosis virus reverse transcriptase after annealing 1
 g of T. cruzi total RNA with Oligo dT adaptor primer (Takara
Shuzo). TcOYE open reading frame (ORF) was amplified with
gene-specific primers from T. cruzi dehydrogenase ORF, i.e.,
sense primer 5 -CGGAATTCATGGCGACGTTCCCT-
GAACTTC-3   and antisense primer 5 -CCGCTCGAGT-
TATTTGTTGTACGTCGGGTA-3   that carried EcoRI and
XhoI restriction sites, respectively, at their 5  end and cDNA first
strand as template by using the following program: 95 C for 5
min, 94 C for 1 min, 56 C for 30 s, and 72 C for 1 min at 30
PCR cycles. Nested PCR amplification was performed with the
first PCR amplification product as a template. The amplified
fragments were cloned into pGEX-4T-1 vector (Amersham Bio-
sciences). At Takara Co., DNA sequences were determined from
both strands by use of a dye terminator system (BigDye Termina-
tor; Applied Biosystems).
Alignment of Primary Structures and Phylogenetic Analysis. The se-
quences of nine members of flavin-dependent oxidoreductase fam-
ily were retrieved from public database. Protein sequences were
aligned by using the CLUSTAL W algorithm and BLOSUM
Clustered Scoring Matrix (22) available at the National Institute
of Genetics, Mishima, Japan. Phylogenetic analyses were per-
formed with the PHYLIP package (23).
Heterologous Expression of the Recombinant Enzyme. The PCR
product encoding TcOYE ORF was digested with EcoRI and
XhoI restriction enzymes and then cloned into the corresponding
sites of the pGEX-4T-1 expression vector (Amersham Bio-
sciences). The resultant expression vector was used for transfor-
mation of Escherichia coli BL21. Transformed cells were cultured
for 6–7 h in the presence of 0.5 mM isopropyl- -d-thiogalacto-
pyranoside (IPTG) and then harvested and sonicated. The soluble
recombinant protein was produced in E. coli BL21 and purified
by affinity chromatography on glutathione (GSH)-Sepharose 4B
resin (Amersham Biosciences), ion exchange chromatography,
and gel filtration according to the manufacturer’s protocol.
Electron Spin Resonance (ESR) Experiments. ESR experiments
were performed as described by Moreno et al. (24). For hydrogen
peroxide, 4-nitroquinoline-N-oxide, nifurtimox, and  -lapa-
chone, the reaction mixture (200  l each) contained 10 mM
NADPH, a reaction buffer (24), 200  g TcOYE, and 2 mM sub-
strate. For menadione, the mixture contained 0.7 mM NADPH,
5 mM Tris/Cl, pH 7.0, 200  g TcOYE, and 0.6 mM substrate.
The mixtures were gassed with argon for 2 min in a small glass
bottle tightly closed with septum. The reaction was started by the
addition of enzyme and substrate and was kept for 3 min at 37 C
or 25 C (for menadione) before recording the spectra of 100  l
mixture in an ESR cell. ESR measurements were performed on a
JEOL X-band spectrometer (JES-RE1XE) and ESR spectra were
recorded under nonsaturating microwave power conditions. The
magnitude of modulation was chosen to optimize the resolution
and the signal to noise ratio of the spectra. The g values were cal-
ibrated with an Mn2  marker. Computer simulation was per-
formed on a Macintosh personal computer using Calleo ESR
version 1.2 (Calleo Scientific Publisher).
Western Blotting and Immunoprecipitation. Polyclonal antibody
against TcOYE was generated as previously described (25) with
300  g recombinant TcOYE in 5 mM Tris/Cl buffer, pH 8.0.
Rabbits were immunized subcutaneously and boosted four times
every 2 wk with the same preparation for 1 mo. Total epimastigote
lysates or pure TcOYE was resolved on 14% SDS-PAGE gels.
Proteins were transferred onto polyvinylidene difluoride mem-
branes (Millipore), blocked with BlockAce (Dainippon Seiyaku),
and cross reacted with rabbit anti–TcOYE polyclonal antibody
before being developed with horseradish peroxidase–labeled
secondary antibody (ECL kit; Amersham Biosciences). For im-
munoblotting, total epimastigote lysates were diluted to 1  g/ l
with PBS and 250  l aliquots were incubated overnight at 4 C
with various concentrations of anti-TcOYE polyclonal antibody.
The immunocomplex was captured by recombinant protein A
agarose beads (Upstate Biotechnology). After centrifugation, the
supernatants were tested for their different reductase activities.
Results
T. cruzi Produces PGs from AA. We used stationary
phase epimastigotes of T. cruzi cultured without exogenous
AA supplement, except for the trace amounts present in se-
rum. Lysates from these cells produced high levels of
PGD2, PGE2, and PGF2  when incubated with 1 mM AA
in the reaction mixture (Fig. 1). In the absence of the 1
mM AA, epimastigote lysates produced high amounts of
PGD2 and PGF2 , whereas PGE2 production decreased al-
most 4.5-fold (Fig. 1). These results suggest that a substan-
tial source of intracellular AA may exist in the parasite. In
addition, heat treatment (100 C for 20 min) inactivated PG
synthesis by the lysates and no PG production was observed
after the incubation of 1 mM AA in the absence of lysates
(unpublished data). The addition of nonsteroidal antiin-
flammatory drugs (3 mM aspirin or 42  M indomethacin)
to the reaction mixture had no inhibitory effects on PG1244 Trypanosoma cruzi naphthoquinone- and nitroheterocycle-metabolizing enzyme
synthesis by T. cruzi lysates although these concentrations
of the drugs are known to inhibit the action of cyclooxyge-
nase from sheep seminal vesicles (16).
Isolation and Cloning of TcOYE Gene. To investigate the
de novo synthesis of PGs, we incubated cell lysates with
1-[14C]PGH2 and then monitored PGF2  synthesis. Under
aerobic conditions, we detected only one major PG syn-
thase activity in the cytosolic fraction, i.e., PGF2  synthase
that depended on NADPH-generating system (Fig. 2 A).
No PGF2  synthesis was detected in the absence of protein
or the presence of heat-inactivated cytosolic fraction (Fig.
2 A), NADPH, membrane fraction, dithiothreitol, and
GSH (unpublished data). However, we detected nonenzy-
matic conversion of PGH2 to PGE2 but not to PGF2  (Fig.
2 A).
To identify the PGFS gene from T. cruzi, we searched
the Expressed Sequence Tags database for a gene homolo-
gous to T. brucei PGF2  synthase (TbPGFS) by using its
amino acid sequence (sequence data are available from
GenBank/EMBL/DDBJ under accession no. AB034727)
and found some homology with an unidentified fragment
of the aldo/ketoreductase gene from T. cruzi (sequence
data are available from GenBank/EMBL/DDBJ under ac-
cession no. AF262056). However, we failed to express a
protein from this gene, indicating the possibility that a non-
functional gene might have been amplified. We then de-
cided to purify native PGFS from the cytosolic fraction of
T. cruzi. After ammonium sulfate fractionation, the active
fraction was purified by sequential HPLC. The overall pro-
cedure resulted in an  1,630-fold purification with a re-
covery of 1%. Pure TcOYE exhibited a specific activity of
700 nmol/min/mg of protein. SDS-PAGE analysis re-
vealed the presence of a single protein band with an appar-
ent molecular mass of 42 kD (Fig. 2 B). Calibration of
TcOYE by gel filtration confirmed the molecular mass of
42 kD (unpublished data), indicating that TcOYE was a
monomeric protein. In addition, pure TcOYE was found
to bind one FMN cofactor and spectroscopic characteriza-
tion revealed visible absorbance spectra characteristic of an
oxidized flavin, with maxima at 462 and 382 nm (Fig. 2 C).
Then, we subjected pure TcOYE to partial amino acid se-
quencing and determined the amino acid sequences from
three internal peptide fragments (Fig. 2 D). Then, we iden-
tified a 1,686-bp full-length cDNA (sequence data are
available from GenBank/EMBL/DDBJ under accession
no. U31282) of the T. cruzi amastigote homologue of the
yeast OYE gene from the database. The cDNA encoded a
1,140-bp ORF that predicted a protein of 379 amino acid
residues with a calculated molecular weight of 42,260 dal-
tons. Cloning and sequencing of the amplified 1,140-bp
ORF fragment revealed one nucleotide mutation with sub-
stitution of the amino acid residue and seven nucleotide
substitutions with the same sense mutations probably due
to T. cruzi strain polymorphism.
Characterization of the TcOYE Gene. A database search
and alignment of the amino acid sequence (Fig. 3) revealed
that TcOYE is a member of the family of flavin-dependent
oxidoreductases including NADPH dehydrogenase, xeno-
biotic reductase, morphine reductase, N-ethylmaleimide
reductase, 2-cyclohexane-one reductase, 12-oxo phytodi-
enoate reductase from bacteria, yeast, fungi, and protozoa.
The TcOYE amino acid sequence showed 16–28% identi-
ties to related proteins from a variety of organisms. Among
them, TcOYE showed 24–28% identity to oxidoreductase
from  Agrobacterium tumefaciens, morphine reductase and
N-ethylmaleimide reductase from Leishmania major, xeno-
Figure 1. PG production by T. cruzi epimastigote lysates. Stationary
growth phase epimastigotes were cultured without the addition of AA
into the culture medium, whereas lysates from these cells were incubated
with or without 1 mM AA. Gray, black, and white bars indicate PGD2,
PGE2, and PGF2 , respectively. PG detection limits were less than 7.8,
7.8, and 3.6 pg/assay for PGD2, PGE2, and PGF2 , respectively. Values
shown are the mean from three independent experiments along with SE. Figure 2. (A) Reduction of PGH2 by native TcOYE. Lane 1, substrate
incubated in the absence of enzyme; lane 2, with 2  g pure TcOYE; lane
3, with 20  g heat-inactivated TcOYE. (B) SDS-PAGE of native
TcOYE. 2  g protein was resolved on a 14% SDS polyacrylamide gel and
detected by Coomassie Brilliant Blue staining. Lane 1: molecular weight
markers; lane 2, pure TcOYE. (C) Absorbance spectrum of 4  g/ l oxi-
dized TcOYE in 0.1 M sodium phosphate buffer, pH 7.0, at 37 C. (D)
Partial amino acid sequences of the three internal fragments from the in-
gel digestion of TcOYE.1245 Kubata et al.
biotic reductase from Pseudomonas aeruginosa, and N-ethyl-
maleimide reductase from E. coli. TcOYE also showed 17–
19% identities to 12-oxo phytodienoate reductase from
tomato and NADPH oxidoreductase from Saccharomyces cere-
visiae and Candida albicans. In addition, phylogenetic analy-
sis supported a premise that Leishmania morphine reductase
is the closest associate of TcOYE (bootstrap value 95%, un-
published data).
Expression of Recombinant TcOYE. We cloned TcOYE
ORF into a pGEX expression vector and produced the re-
combinant TcOYE as a soluble GSH–transferase fusion
protein in E. coli after IPTG induction. We purified the re-
combinant TcOYE by chromatography on GSH-Sepha-
rose affinity and ion exchange columns (Fig. 4 A). Pure re-
combinant TcOYE was found to bind one FMN cofactor
and exhibited visible absorbance spectra characteristic of an
oxidized flavin identical to the native TcOYE. SDS-PAGE
showed a single protein band of 42 kD (Fig. 4 A). Crude
proteins from E. coli BL21 expressing pGEX-TcOYE, but
not lysates from E. coli host or E. coli transformed with
empty pGEX vector, showed 9,11-endoperoxide PGH2 re-
ductase activity and pure recombinant TcOYE exhibited a
specific activity of 760 nmol/min/mg of protein. These
data indicate that the detected 9,11-endoperoxide PGH2
reductase activity depended on T. cruzi protein and not on
any contaminating activity from the host or vector. We
used the recombinant TcOYE as an antigen to generate
rabbit anti–TcOYE polyclonal antibody. We incubated ly-
sates from T. cruzi and T. brucei with anti-TbPGFS poly-
clonal serum and anti-TcOYE polyclonal antibody, respec-
tively, to investigate the specificity of both antibodies.
Western blot analysis revealed no cross reaction between
the two parasite lysate proteins, indicating the high speci-
ficity of each antibody. Instead, we detected only bands
corresponding to TcOYE and TbPGFS (Fig. 4 B). These
results demonstrate that T. cruzi lacks a 33-kD aldo/keto
reductase despite the presence of the gene and T. brucei
does not have the 42-kD OYE homologue. Moreover, at-
tempts to identify TcOYE-generated PGF2  revealed that
the reaction product resulting from the reduction of 9,11-
endoperoxide PGH2  displayed a retention time corre-
sponding to that of the authentic PGF2  (Fig. 4 C, top and
bottom) on LC-MS. The [M-H]  ions of TcOYE-gener-
ated product and that of the authentic PGF2  were identical
and observed at m/z 353.2 (Fig. 4 D, top and bottom).
Under these experimental conditions, PGD2, PGE2, 11- -
PGE2, PGF2 , and PGJ2 each eluted at different retention
times (Fig. 4 C, middle). These LC-MS results demonstrate
that TcOYE-generated product is PGF2  and confirm the
fact that TcOYE catalyzes specifically the reduction of
9,11-endoperoxide PGH2 into PGF2 .
TcOYE Reduces Peroxides and Trypanocidal Agents.
OYEs can oxidize both NADPH and NADH (2, 5, 26) in
the presence of various substrates. Because these enzymes
catalyze the NAD(P)H-dependent reduction of quinones
and nitroderivatives (3, 5, 27), we hypothesized that
TcOYE may reduce naphthoquinone and nitroheterocy-
clic trypanocidal agents thus contributing to the metabo-
lism of antitrypanosomal drugs. We tested this idea by
assessing TcOYE reductase activity under aerobic or
anaerobic conditions. In the presence of oxygen, TcOYE
completely reduced PGH2 to PGF2  with NADPH-gener-
ating system (Fig. 2 A). No PGF2  formation was observed
with NADPH or NADH (unpublished data) probably due
to the depletion of the cofactors as a result of preincubation
of the enzyme with cofactors in the absence of PGH2 be-
Figure 3. Multiple sequence
alignment of deduced TcOYE
amino acid sequence with represen-
tative members of the flavin-depen-
dent oxidoreductases family. The
amino acid sequences were taken
from the public database. TcOYE is
aligned with: LmMR, L. major mor-
phine reductase (sequence data are
available from GenBank/EMBL/
DDBJ under accession no.
AL390114); Agroba, Agrobacter tume-
faciens oxidoreductase (accession no.
NP_535816); Methorizo, Mesorhizo-
bium loti morphinone reductase (ac-
cession no. NP_103610); Ec, E. coli
N-ethylmaleimide reductase (acces-
sion no. NP_416167); Paer, P.
aeruginosa xenobiotic reductase (ac-
cession no. NP_253046); Avinel,
Azotobacter vinelandi 2-cyclohexane-
one reductase (accession no.
AB025798); Tomato, Lycopersicon es-
culentum 12-oxo phytodienoate re-
ductase (accession no. AJ242551);
Sc,  Saccharomyces cerevisiae NADPH
dehydrogenase 1 (accession no. Q02899); Candida, C. albicans NADPH dehydrogenase estrogen binding protein (accession no. P43084). * and : indicate
identical amino acids and conserved amino acid substitutions, respectively. Boxes indicate the peptide sequences identified from purified native TcOYE.1246 Trypanosoma cruzi naphthoquinone- and nitroheterocycle-metabolizing enzyme
cause NADPH and NADH are readily oxidized by OYEs
in the presence of oxygen, which is an opportunistic sub-
strate of these enzymes (2). In addition, TcOYE showed only
a very low reductase activity toward menadione,  -lapa-
chone, and 4-nitroquinoline-N-oxide, and no activity to-
ward nifurtimox in the presence of oxygen. On the other
hand, anaerobic reduction of 9,11-endoperoxide PGH2 by
TcOYE led to a specific activity of the same order of mag-
nitude to that of reduction under aerobic conditions and
TcOYE used either NADPH or NADH as cofactor.
TcOYE Vmax and/or specific activity and Km values for per-
oxides and trypanocidal agents are shown in Table I. Under
anaerobic conditions, TcOYE also reduced peroxides (hy-
drogen peroxide and butyl hydroperoxide) and trypano-
cidal agents (menadione,  -lapachone, nifurtimox, and
4-nitroquinoline-N-oxide). Except for 4-nitroquinoline-
N-oxide, TcOYE showed specific activity values of the
same order of magnitude (Table I). Under aerobic condi-
tions, TcOYE exhibited only 4.5, 14, and 4% of the anaer-
obic reductase activity toward menadione,  -lapachone,
and 4-nitroquinoline-N-oxide, respectively. No reductase
activity could be observed toward benznidazole, crystal vi-
olet, etc. under both conditions (Table I). In the presence
of NADH as cofactor, TcOYE exhibited almost 1.5-, 2.2-,
and 1.8-fold higher enzymatic activity toward  -lapa-
chone, mevinolin, and econazole, respectively, as com-
pared with the reduction of these substrates in the presence
of NADPH. In contrast, all other drugs were reduced with
Figure 4. (A) Purification of recombinant
TcOYE. TcOYE was expressed as a fusion protein
with GSH in E. coli BL21. Lane 1, molecular
weight markers; lane 2, lysates from noninduced E.
coli BL21 cells expressing pGEX-TcOYE; lane 3,
lysates from IPTG-induced E. coli BL21 cells ex-
pressing pGEX-TcOYE; lane 4, after affinity chro-
matography; lane 5, pure recombinant TcOYE. (B)
Immunoblot analyses of cell extracts from T. cruzi
epimastigote and T. brucei bloodstream form. After
blotting, the membranes were incubated with anti-
TcOYE or anti-TbPGFS polyclonal antibodies. On
the left, SDS-PAGE of the lysates corresponding to
T. brucei (Tb) and T. cruzi (Tc) is shown. The pro-
teins were detected with Coomassie Brilliant Blue
(CBB). The middle shows a Western blot for pro-
teins incubated with anti-TcOYE polyclonal anti-
body. The right shows a Western blot for proteins
incubated with anti-TbPGFS polyclonal antibody.
(C) LC-MS chromatograms of the relative ion in-
tensity for TcOYE-generated PGF2 . Top, stan-
dard PGF2 ; left, substrate (9,11-endoperoxide
PGH2) showing traces of nonenzymatic degrada-
tion products (PGE2, 11 -PGE2, PGD2, and PGJ2);
bottom, PGF2  resulting from the reduction of the
substrate by TcOYE. The chromatograms for
PGE2, 11 -PGE2, PGD2, and PGH2 were visual-
ized at m/z   351.2, whereas that of PGF2  was
monitored at m/z    353.2. (D) Mass spectra
showing the [M-H]   ions of authentic PGF2 
(top), PGH2  (middle), and TcOYE-generated
PGF2  (bottom).1247 Kubata et al.
the highest reduction rate in the presence of NADPH as
cofactor rather than NADH. No reduction and oxidation
of carbonyl and hydroxyl groups, respectively, were ob-
served after TcOYE incubation with either 1-[14C]PGD2,
PGE2, or PGF2  (unpublished data), indicating that TcOYE
did not catalyze the reduction of PGD2, PGE2 into PGF2 ,
or the formation of any 15-oxo-derivative of these PGs.
However, additional bands observed upon the incubation
of T. cruzi lysates with 1-[14C]PGH2 suggest the presence of
different enzymes in the lysates that produce 15-oxo– or
15-keto–containing structures.
TcOYE Catalyzes the Formation of Radical Anions from
Naphthoquinones but Not from Nitroheterocycles. The find-
ing that TcOYE catalyzed the anaerobic reduction of try-
panocidal drugs prompted us to explore its involvement in
either xenobiotic reduction (parasite defense mechanism)
or the redox cycling process (generation of free radicals).
Therefore, we studied the interaction of TcOYE with hy-
drogen peroxide, 4-nitroquinoline-N-oxide, nifurtimox,
menadione,  -lapachone, and mevinolin. The incubation
of menadione or  -lapachone with recombinant TcOYE
generated multiline ESR spectra identified as the respective
semiquinone radical metabolites (Fig. 5, A and B, top). The
semiquinone radical spectra were additionally analyzed by
computer simulation (Fig. 5, A and B, bottom). The mag-
Table I. Substrate Specificity of the Recombinant TcOYE
Substrate Cofactor Km Vmax/specific activity
(100  M) ( M) (nmol/min/mg)
9,11-endoperoxide PGH2 NADH — 554
NADPH 5.0 766
Hydrogen peroxide NADPH 2.3 99
BHPa NADPH ND 282
Menadione NADH — 499
NADPH 0.82 700
 -lapachone NADH 0.17 650
NADPH — 433
4-nitroquinoline-N-oxide NADH — 759
NADPH 9.5 1,110
Nifurtimox NADH — 290
NADPH 19.0 353
Phenazine methosulfateb NADPH 10.4 235
Mevinolinc NADH ND 555
12-oxo phytodienoic acidd NADPH ND 152
9-oxo ODEe NADPH ND 54
Econazolef NADH ND 43
Benznidazole — ND n.d.
Miconazoleg — ND n.d.
Ketoconazoleh — ND n.d.
Crystal violeti — ND n.d.
BHTj — ND n.d.
BHAk — ND n.d.
n.d., not detected.
at-Butyl hydroperoxide
b5-Methyl-phenazinium methyl sulfate
c2 ,6 -dimethyl-8 -(2-methyl-1-oxobutoxy)-mevinic acid lactone
d4-oxo-5 -(2Z-pentenyl)-2-cyclopentene-1 -octanoic acid
e9-oxo-10E, 12Z-octadecadienoic acid
f1-[2-([4-Chlorophenyl]methoxy)-2-(2,4-dichlorophenyl)ethyl-1H-
imidazole
g1-[2,4-Dichloro- -([2,4-dichlorobenzyl]-oxy)phenethyl]imidazole
hcis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-
ylmethyl)-1,3-dioxolan-4-yl-methoxy]phenyl]piperazine
iN-[4-[Bis[4-(dimethylamino)-phenyl]methylene]-2,5-cyclohexadien-
1-ylidene]-N-methyl-methanaminium chloride
j(2,6-Di-tert-butyl-p-cresol)
k[2(3)-tert-butyl-4-hydroxianisole]
Figure 5. Semiquinone and superoxide radical anion spectra obtained
from menadione and  -lapachone. On the top, ESR spectrum of the
semiquinone radical anion generated by the action of TcOYE on mena-
dione after anaerobic incubation is shown. The bottom shows a computer
simulation spectrum of the semiquinone radical anion with a g value of
2.0044 and hyperfine coupling constants a(4 H)   3.0 G, a(3 H)   0.66 G,
and a maximum slope of line width  Hmsl   0.15 G. (B) On the top,
ESR spectrum of the semiquinone radical anion generated by the action
of TcOYE on  -lapachone after anaerobic incubation is shown. The
bottom shows a computer simulation spectrum of the semiquinone radical
anion with a g value of 2.0046 and hyperfine coupling constants a(1 H)  
3.3 G, a(2 H)   1.7 G, and  Hmsl   0.7 G. (C) ESR spectrum of O2
.-
 g//  
2.09 and g⊥   2.005 formed in the reaction of semiquinone radical anion
with O2 in 9 mM Tris/Cl, pH 7.4, at  155 C. g// component is magni-
fied five times.1248 Trypanosoma cruzi naphthoquinone- and nitroheterocycle-metabolizing enzyme
netic parameters of the semiquinone radicals from com-
puter simulation agreed well with those obtained with
TcOYE. No ESR signals could be detected in the absence
of either the enzyme or substrate or upon the incubation of
naphthoquinones with heat-denatured TcOYE. The sub-
sequent reoxidation of both menadione and  -lapachone
radical anions by O2 resulted in superoxide anion-free radi-
cal generation (Fig. 5 C). Our findings confirmed the in-
volvement of TcOYE in free radical generation from at
least naphthoquinone drugs. No ESR signals related to any
other free radicals could be detected with 4-nitroquino-
line-N-oxide, nifurtimox, or mevinolin.
Naphthoquinone and Nitroheterocyclic Drugs Inhibit the En-
doperoxide Reductase Activity of TcOYE. Several naphtho-
quinone and nitroheterocyclic compounds are inhibitors
and/or redox cycling substrates for flavoprotein enzymes
(9, 15). To gain insight into the inhibitory effect of these
compounds on 9,11-endoperoxide PGH2 reductase activity
of TcOYE, we investigated the effects of these drugs on
9,11-endoperoxide PGH2 reduction by TcOYE. In the
presence of up to 200  M menadione,  -lapachone, or
4-nitroquinoline-N-oxide, TcOYE exhibited 68, 86, or
76%, respectively (Fig. 6), of the control (9,11-endoperox-
ide PGH2 reductase) activity, indicating that these drugs
were weak inhibitors. In contrast, nifurtimox inhibited en-
doperoxide reduction in a dose-dependent manner, with
200  M nifurtimox allowing only 6% of the TcOYE activ-
ity (Fig. 6).
TcOYE Is the Major Drug Metabolizing Enzyme. To re-
veal a possible role for TcOYE as a target enzyme in the
metabolism of trypanocidal drugs and generation of free
radicals, we incubated cell lysates with anti-TcOYE poly-
clonal antibody and confirmed the immunoprecipitation of
TcOYE by Western blot analysis (Fig. 7 A). After captur-
ing the immunocomplex with recombinant protein A aga-
rose beads, the resulting lysate supernatants exhibited only
trace reductase activity toward endoperoxide PGH2 and
 -lapachone compared with untreated or anti-TbPGFS poly-
clonal antibody-treated lysates (Fig. 7 B and Table II). Sur-
prisingly, under our experimental conditions, menadione,
nifurtimox, and 4-nitroquinoline-N-oxide reduction was
abolished after the immunoprecipitation of TcOYE (Table
II), demonstrating that under anaerobic conditions TcOYE
might be a major reductase of the parasite for peroxides,
naphthoquinones, and nitroheterocyclic compounds and
that T. cruzi also possesses other minor 9,11-endoperoxide
PGH2– and/or  -lapachone–reductases.
Discussion
Here, we have shown that T. cruzi lysates synthesize
PGs from AA. This parasite also produces high levels of
PGD2 and PGF2 , and a decreased amount of PGE2 even
in the absence of AA addition. These results suggest the
existence of a free intracellular AA source in the epimas-
tigotes of T. cruzi and probably the presence of a PGE2-
metabolizing system in the parasite. Indeed, the presence
of AA in the parasite cells has been demonstrated by sev-
eral earlier investigations (28, 29). These studies showed
around 0.7% AA in phospholipid fraction of T. cruzi Y
strain epimastigotes (28), whereas fatty acid composition
of individual phospholipids revealed 1.3% and trace
amount of AA in phosphatydilcholine and phosphatidyl-
ethanolamine, respectively. Although de novo synthesis of
AA from acetate is not known in trypanosomes, T. cruzi
needs AA as a component of the building block of its
phospholipid structure and AA, along with other fatty ac-
ids, is responsible for the fluidity of cell membranes in this
organism. It has been demonstrated that to meet its AA
needs the uptake of this fatty acid from its environment
must occur (29). This intracellular arachidonate source
may provide the substrate needed for PG production by
the parasite in the absence of exogenously added AA. On-
going investigations on PG metabolism in T. cruzi would
probably help to unravel any PGE2-degrading enzyme in
this parasite.
Figure 6. (A) Trypanocidal drug dose-dependence inhibition of 9,11-
endoperoxide PGH2 reduction by TcOYE. The enzymatic activity of the
control (0  M drug) was given a 100% value to calculate the percentage
of residual activity.  , menadione;  ,  -lapachone;  , nifurtimox;  ,
4-nitroquinoline-N-oxide. Data are expressed as the mean along with SE
from three independent experiments.
Figure 7. (A) Immunoblot analysis of
the supernatant from T. cruzi epimasti-
gote cell lysates after immunoprecipita-
tion with anti-TcOYE polyclonal anti-
body. Lane 1, lysates incubated without
primary antibody; lane 2, anti-TbPGFS
polyclonal antibody–treated lysates; lane
3, anti-TcOYE polyclonal antibody–
treated lysates. After immunoblotting,
the membrane was incubated with anti-
TcOYE polyclonal antibody. (B) Super-
natants from immunoprecipitated lysates
were tested for their 9,11-endoperoxide
PGH2  reductase activity. Lanes 1–3
correspond to those in A.1249 Kubata et al.
In this study, we have also reported on the biochemical
isolation, cloning, and molecular characterization of a
TcOYE that has limited homology to OYEs from other
sources. In addition, we obtained direct evidence for the
implication of TcOYE in the synthesis of a biologically ac-
tive molecule, i.e., PGF2 , and in the metabolism of try-
panocidal compounds with generation of free radicals from
naphthoquinone drugs. The findings that T. cruzi produces
PGs and that TcOYE catalyzes PGF2  formation raise ques-
tions about T. cruzi biology and the interaction of this or-
ganism with its mammalian host. PGs are potent mediators
of physiological and pathological responses (30–32), some
of which are observed in Chagas’ disease (33). In addition,
it has been reported that PGE2 and PGF2  may play a signal
coupling role during phagocytosis in the protozoan parasite
Amoeba proteus, because they elicit vacuole formation (34),
whereas PGD2 was shown to play an important role in T.
brucei cell growth regulation by inducing programmed cell
death (unpublished data). However, whether or not T.
cruzi–derived PGs play similar roles remains to be investi-
gated. We have identified a gene whose flavoprotein prod-
uct TcOYE catalyzes PGF2  synthesis in this parasite. This
result is in contrast to previous observations that in other
trypanosomatids, i.e., T. brucei (17), Leishmania, and Crithidia
fasciculata (unpublished data) PGF2  synthesis is catalyzed by
aldo/keto reductases that are markedly different from
TcOYE. These findings suggest that for unknown reasons
different species of the phylum trypanosomatid have
evolved different enzymes to synthesize PGF2  during the
course of evolution.
Our results also indicate that TcOYE could reduce
naphthoquinone and nitroheterocyclic drugs. These drugs
can undergo either one- or two-electron reduction. The
one-electron reduction produces semiquinone and nitro
radical anions from naphthoquinone and nitroheterocyclic
drugs, respectively, with the concomitant formation of su-
peroxide radical anions that cause oxidative damage (35,
36). The two-electron reduction of quinones leads to the
formation of hydroquinones without producing semi-
quinone-free radical intermediates and represents a detoxi-
fication pathway for many organisms (37, 38). Alternatively,
the successive two-electron reduction of nitroaromatic com-
pounds ultimately produces amino substituents (39). One
of the first demonstrations of the enzymatic formation of
drug-derived free radicals in eukaryotic organisms was made
by incubating  -lapachone (14, 40) and then nifurtimox
(12) with intact cells or lysates of T. cruzi and identifying
the semiquinone or nitro radical anions by ESR. Although
 -lapachone and nitro reductase activities have been de-
tected in epimastigote mitochondria (12, 14) and the dam-
aging effect of  -lapachone has been demonstrated (41,
42), the parasite proteins involved in the reduction of both
drugs are not well known. Our data support a role for
TcOYE in the specific one-electron reduction of menadi-
one and  -lapachone to semiquinone radicals with the
concomitant generation of a superoxide anion radical. Be-
cause OYEs have been so far isolated from yeasts, plants,
and bacteria, and that these enzymes catalyze the two-elec-
tron reduction of quinones (2) with no semiquinone radical
production (2, 43), the identification of OYE that catalyzes
the specific one-electron reduction of menadione and
 -lapachone in a parasitic protozoa appears to be unique. On
the other hand, TcOYE seems to catalyze the two-electron
reduction of nitroheterocyclic drugs with no obvious nitro
radical anion production. These findings are in agreement
with the study by Karplus et al. (44), who found that bacte-
rial OYE also catalyzed the two-electron reduction of nitro
compounds.
Unexpectedly, we also discovered that all reductase ac-
tivities of epimastigotes were abolished by immunoprecipi-
tation of the TcOYE lysates with anti-TcOYE polyclonal
antibody except those toward endoperoxide and  -lapa-
chone. Indeed, several investigators have proposed T. cruzi
trypanothione reductase (TR) and lipoamide dehydroge-
nase to be major naphthoquinone and nitroheterocyclic
drug–metabolizing enzymes (9, 15, 45, 46). Both enzymes
catalyze the one-electron reduction of naphthoquinone
and nitroheterocyclic drugs to semiquinone and nitro radi-
cal anions, respectively, with the concomitant generation
of superoxide radical anions. However, the failure of over-
expressed TR to alter sensitivity to agents that induce oxi-
dative stress in T. cruzi (47), as well as the lack of a correla-
tion between either nifurtimox sensitivity and the ability to
catalyze nifurtimox redox cycling or nifurtimox sensitivity
and the amount of TR mRNA (48), argue against any ma-
jor role for TR in generating oxidative stress. Our observa-
tion that anti-TcOYE polyclonal antibody abolished the
major naphthoquinone and nitroheterocycle reductase ac-
tivities means that either TR and lipoamide dehydrogenase
are not involved in the redox cycling process of the para-
Table II. Effect of Anti-TcOYE Polyclonal Antibody Treatment of T. cruzi Lysates on Drug Reduction
Percent residual reductase activity toward:
Sample Menadione  -lapachone Nifurtimox 4-nitroquinoline-N-oxide
Lysates from treatment with anti-TcOYE polyclonal antibody n.d. 10 ( 2) n.d. n.d.
Lysates from treatment with anti-TbPGFS polyclonal antibody 98 ( 8) 103 ( 3) 100 ( 5) 100 ( 10)
Lysates from treatment with bovine IgG 100 ( 4) 100 ( 6) 100 ( 10) 100 ( 6)
n.d., not detected. Values shown are the mean along with SE from three independent experiments.1250 Trypanosoma cruzi naphthoquinone- and nitroheterocycle-metabolizing enzyme
site, thus supporting previous studies (47, 48), or the
enzymes do not catalyze these reactions by an anaerobic
pathway. Although the parasite still contains minor endo-
peroxide and/or  -lapachone reductases other than TcOYE,
our results indicate that TcOYE might be the major en-
zyme used by T. cruzi to catalyze the redox cycling of
naphthoquinones and the reduction of other trypanocidal
drugs. Therefore, this study provides new insight in our
understanding of trypanocidal drug metabolism and stresses
the need for additional research on TcOYE gene disrup-
tion and analysis of its biological relevance.
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